Category: Oncology

Heat Biologics acquires Texas-based immune therapy firm

Durham-based Heat Biologics has inked a deal to acquire an 80 percent controlling interest in Pelican Therapeutics Inc., an immuno-oncology company based in Austin, Texas. The deal pays up to $500,000 up front to Pelican shareholders, which also includes stock, milestones, sublicensing, income payments and loans.

Researchers create novel model that reveals cellular, molecular events driving leukemia progression

Mount Sinai researchers have created a novel model that shows the step-by-step progression from normal blood cells to leukemia and its precursor diseases, creating replicas of the stages of the disease to test the efficacy of therapeutic interventions at each stage, according to a study to be published in Cell Stem Cell. This research marked the first time scientists have been able to transplant leukemia from humans to a test tube and then into mice for study, a landmark feat that will allow for valuable research to help find therapies for blood cancer patients in the future.

Aptose Biosciences to Present at Biotech Showcase 2017 Conference

Aptose Biosciences Inc. , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Biotech ShowcaseTM 2017 Conference on Tuesday, January 10th at 9:00 a.m. PST in San Francisco, CA. The audio webcast will be archived shortly after the live event and will be available through the Aptose website at www.aptose.com .

Cellectar Biosciences to Present at the 9th Annual Biotech Showcase

Cellectar Biosciences, Inc. , an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim Caruso will present at the Biotech Showcase in San Francisco on January 11, 2017 at 10:00 AM PT in Room 2 . “We look forward to discussing the continued advancement of our lead PDC program, CLR 131, as well as providing relevant updates on our other product candidates and corporate performance,” said Mr. Caruso.

OncoMed Announces Year-End Cash Balance and 2017 Outlook

OncoMed Pharmaceuticals Inc. , a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today pre-announced its 2016 year-end cash balance and reviewed key anticipated events for 2017. OncoMed ended 2016 with approximately $184.6 million in cash.

Tiny Boston Biotech Pieris Nabs $570 Million+ Cancer Deal With French Powerhouse Servier

Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including Pieris’ proprietary dual checkpoint inhibitor PRS-332 Alliance includes four additional bispecific programs and may be expanded to a total of eight immuno-oncology programs ; Pieris has option to co-develop and retain US rights for 4 of these programs, including PRS-332 Pieris to receive EUR30 million upfront, up to EUR324 million in success-based payments for PRS-332, up to EUR193 million in success-based payments for each of the other programs and up to double-digit royalties Pieris will host an investor conference call on Thursday, January 5, 2017 at 8:30 AM to discuss the collaboration : PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its … (more)